InvestorsHub Logo
Followers 2
Posts 118
Boards Moderated 0
Alias Born 05/31/2011

Re: None

Tuesday, 05/02/2017 9:16:12 AM

Tuesday, May 02, 2017 9:16:12 AM

Post# of 34787
Could be very big for TPIV too!


TPIV200 has the same fast track type designation that Durvalumab had... and we have interim data by end of this year for this study. Could receive fast track approval for ovarian cancer for P2 results!

TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer

https://clinicaltrials.gov/ct2/show/NCT02764333?term=NCT02764333&rank=1



Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRKR News